VERU INC. - COMMON STOCK

Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual Meeting

07 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Announces Positive Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer Presented at the 2021 ASCO Annual Meeting

07 Jun 2021 07:15:00 By Nasdaq GlobeNewswire

Veru to Present at the Jefferies Virtual Healthcare Conference

25 May 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Announces Acceptance of Two Abstracts for Presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

24 May 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Enrolls First Patient in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients

19 May 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues

12 May 2021 05:30:00 By Nasdaq GlobeNewswire

Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021

05 May 2021 07:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2021 Second-Quarter Financial Results, Host Conference Call on May 12th

28 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Announces Presentation of Phase 2 Study of Enobosarm -- a Selective Androgen Receptor Targeting Agent in Metastatic AR+ER+HER2- Breast Cancer at 2021 ESMO Breast Cancer Congress

21 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Veru to Present at the Oppenheimer 31st Annual Healthcare Conference

09 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Exploring Strategic Alternatives for its Legacy Female Health Business

08 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

Veru to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences Conference

02 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Receives FDA Agreement to Advance VERU-111 into Phase 3 Study in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)

01 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Submits New Drug Application for Proprietary TADFIN for BPH

23 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Announces Pricing of Public Offering of Common Stock

17 Feb 2021 20:30:00 By Nasdaq GlobeNewswire

Veru Announces Proposed Public Offering of Common Stock

17 Feb 2021 15:01:00 By Nasdaq GlobeNewswire

Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 First Quarter

10 Feb 2021 05:30:00 By Nasdaq GlobeNewswire

Veru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

08 Feb 2021 06:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call on February 10th

27 Jan 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Targeted Agent, Inhibits Hormone Receptor Positive Metastatic Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4/6 Inhibitor Therapies

19 Jan 2021 07:30:01 By Nasdaq GlobeNewswire